Tushar Tuliani, MD
Interventional Cardiology · Medford, ORNPI 1821377961
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.9%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Medtronic at 32.8% of the total. Reporting peaked in 2019 at $4,726 and has fallen 98.2% since, to $85 in 2025.
Across 153 payments — averaging $67.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Edwards Lifesciences$2K
- Abbott$2K
- Philips North America LLC$1K
- Penumbra, Inc.$515
- Novartis$106
- plus $922 from 22 others
What the payments were for
- Grants$1,12311%
- Travel & lodging$4,14340%
- Food & beverage$5,04949%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 33 | $3,389 |
| Edwards Lifesciences | 14 | $2,110 |
| Abbott | 41 | $1,896 |
| Philips North America LLC | 8 | $1,390 |
| Penumbra, Inc. | 10 | $515 |
| Novartis | 7 | $106 |
| Abiomed | 4 | $100 |
| Biotronik Inc. | 2 | $97 |
| Pfizer | 5 | $82 |
| Opsens Inc. | 3 | $80 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Bard Peripheral Vascular, Inc. | 1 | $62 |
| Atricure, Inc. | 1 | $50 |
| Johnson & Johnson | 3 | $47 |
| Angiodynamics, Inc. | 1 | $40 |
| Boston Scientific | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Shockwave Medical, Inc | 1 | $25 |
| Merck | 1 | $21 |
| Teleflex LLC | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,327 in reported general payments places this provider in the 65th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $41,997 |
| BrilintaTicagrelor | 11 | $9,402 |
| XareltoRivaroxaban | 12 | $8,618 |
| Rosuvastatin Calcium | 102 | $1,282 |
| Atorvastatin Calcium | 127 | $1,160 |
| Metoprolol Succinate | 97 | $1,082 |
| Carvedilol | 80 | $733 |
| Valsartan | 23 | $723 |
| ClopidogrelClopidogrel Bisulfate | 60 | $616 |
| Amlodipine Besylate | 94 | $557 |
| Losartan Potassium | 42 | $382 |
| Potassium Chloride | 21 | $251 |
| Ezetimibe | 23 | $223 |
| Telmisartan | 15 | $204 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 21 | $193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $41,99737 claims |
| AstraZenecaBrilinta | $16 | $9,40211 claims |
| Johnson & JohnsonXarelto | $47 | $8,61812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Medford
- Alyssa CorleyMedford$9K
- Christopher CannonMedford$7K
- Rohit MalhotraMedford$4K
- Kent DautermanMedford$2K
- Jaekyoung HongMedford$2K
- Mark MoranMedford$1K
- Roger DreilingMedford$856
- Jason WollmuthPortland$749K
- Saurabh GuptaBend$550K
- Ethan KorngoldPortland$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.